Skip to main content

The Important New Drug Target in Cardiovascular Medicine - the Vascular Glycocalyx

Buy Article:

$63.00 plus tax (Refund Policy)

The process of atherothrombosis is known to involve endothelial pathology (first drug target), plaque formation (second drug target) and thrombosis (third drug target). However it has recently been postulated that, even before endothelial pathology occurs, the very first step in the process of atherothrombosis is dysfunction of the arterial glycocalyx that lies between the endothelial cells and the blood [1]. So there are really four drug targets, and perhaps the arterial glycocalyx will become the most important for future early prevention of people at risk. We will review the data available on the relationship of glycocalyx dysfunction to risk factors for atherothrombosis and indicate the areas of research that are required to elucidate this important new subject. Up to the present time, hyperglycaemia and oxidised LDL have been identified as causing glycocalyx dysfunction, and we will seek publications on drugs that modify these effects. Attempts are being made to explore the possibility of drug-induced reversal of hyperglycaemia-induced glycocalyx dysfunction. Progress is, however, dependent on grants being made available for work with the essential large animal (pig) experimental model for testing glycocalyx function. Such grants have hitherto not been sufficiently forthcoming, and this needs to be brought urgently to the attention of the pharmaceutical industry.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Diabetes; proteoglycans; shear stress; vascular injury

Document Type: Research Article

Publication date: 01 June 2009

More about this publication?
  • Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more